CompletedNot Applicable

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines

Canada175 participantsStarted 2011-06-01

Plain-language summary

This study evaluated the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of forehead lines (facial rhytides) when also administered to frown lines (glabellar rhytides).

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Moderate to severe forehead lines Exclusion Criteria: * Current or previous botulinum toxin treatment of any serotype within one year * Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis * Prior facial cosmetic surgery (e.g. prior periorbital surgery, facial lift, brow lift, eyelid lift or eyebrow surgery) * Facial laser or light treatment, microdermabrasion, or superficial peels within 3 months * Oral retinoid therapy within one year

What they're measuring

Percentage of Participants Achieving a Score of None or Mild by Investigator-Assessed Facial Wrinkle Scale With Photonumeric Guide (FWS) in Forehead Lines at Maximum Eyebrow Elevation

Timeframe: Day 30

Percentage of Participants Achieving a Score of None or Mild by Subject-Assessed Facial Wrinkle Scale With Photonumeric Guide (FWS) in Forehead Lines at Maximum Eyebrow Elevation

Timeframe: Day 30

Trial details

NCT IDNCT01391299

SponsorAllergan

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2011-10-18

Results submitted2012-10-26

View on ClinicalTrials.gov More Facial Rhytides trials